Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Astrocytic Tumor — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm
Neuroepithelial Neoplasm
Glioma
Astrocytic Tumor

Subtype

Astrocytic Tumor

CI-CAN-00001839Explore in graph →

Non-malignant507 active trials2 approved drugs67 evidence items

NCIt: C6958
MeSH: D001254

Overview
Statistics
Survival
Genomics2
Variants & evidence67
Drugs26
Trials1861
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (50)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 26–50 of 50 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).
· Neuro Oncol · 2014 · PMID 24311637 · validated civic_curation pubmed
Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology.
· Acta Neuropathol · 2016 · PMID 26810070 · validated civic_curation pubmed
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.
· J Clin Oncol · 2016 · PMID 27001570 · validated civic_curation pubmed
A Unique Case Report of Infant-Type Hemispheric Glioma (Gliosarcoma Subtype) with TPR-NTRK1 Fusion Treated with Larotrectinib.
· Pathobiology · 2022 · PMID 35034013 · validated civic_curation pubmed
Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor.
· J Clin Oncol · 2012 · PMID 22162573 · validated civic_curation pubmed
Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy.
· Cancer Discov · 2016 · PMID 27683556 · validated civic_curation pubmed
Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.
· J Transl Med · 2014 · PMID 25524464

Showing 26–50 of 50 publications

← Previous
1
2
Next →

· validated civic_curation

Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.

· Oncologist · 2020 · PMID 32043779 · validated civic_curation pubmed

Activity of Pemigatinib in Pilocytic Astrocytoma and FGFR1N546K Mutation.

· JCO Precis Oncol · 2022 · PMID 35507888 · validated civic_curation pubmed

Mosaicism for Receptor Tyrosine Kinase Activation in a Glioblastoma Involving Both PDGFRA Amplification and NTRK2 Fusion.

· Oncologist · 2021 · PMID 34041811 · validated civic_curation pubmed

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.

· JCO Precis Oncol · 2024 · PMID 38603650 · validated civic_curation pubmed

Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.

· Oncotarget · 2015 · PMID 26423602 · validated civic_curation pubmed

PTEN gene mutations are seen in high-grade but not in low-grade gliomas.

· Cancer Res · 1997 · PMID 9331072 · validated civic_curation pubmed

CDKN2A/B Loss Is Associated with Anaplastic Transformation in a Case of NTRK2 Fusion-positive Pilocytic Astrocytoma.

· Neuropathol Appl Neurobiol · 2019 · PMID 29804288 · validated civic_curation pubmed

MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas.

· Acta Neuropathol · 2010 · PMID 21046410 · validated civic_curation pubmed

NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.

· Mod Pathol · 2020 · PMID 31375766 · validated civic_curation pubmed

Entrectinib demonstrates prolonged efficacy in an adult case of radiation-refractory NTRK fusion glioblastoma.

· Neurooncol Adv · 2022 · PMID 35673607 · validated civic_curation pubmed

ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.

· Sci Transl Med · 2016 · PMID 26936505 · validated civic_curation pubmed

Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.

· Mol Cancer Ther · 2013 · PMID 23960094 · validated civic_curation pubmed

Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

· Cancer Res · 2010 · PMID 20354191 · validated civic_curation pubmed

Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.

· Clin Cancer Res · 2018 · PMID 30171048 · validated civic_curation pubmed

Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.

· Oncotarget · 2017 · PMID 28002790 · validated civic_curation pubmed

Tyrosine receptor kinase B is a drug target in astrocytomas.

· Neuro Oncol · 2017 · PMID 27402815 · validated civic_curation pubmed

Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.

· Mol Cancer Ther · 2015 · PMID 25939761 · validated civic_curation pubmed

Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma.

· Proc Natl Acad Sci U S A · 2012 · PMID 22203985 · validated civic_curation pubmed